![]() |
Name |
Aplojaveediin B
|
Molecular Formula | C13H18O4 | |
IUPAC Name* |
2,6-dihydroxy-4-(5-hydroxypentyl)-3-methylbenzaldehyde
|
|
SMILES |
CC1=C(C(=C(C=C1CCCCCO)O)C=O)O
|
|
InChI |
InChI=1S/C13H18O4/c1-9-10(5-3-2-4-6-14)7-12(16)11(8-15)13(9)17/h7-8,14,16-17H,2-6H2,1H3
|
|
InChIKey |
CSLRUQFXTRFIRS-UHFFFAOYSA-N
|
|
Synonyms |
Aplojaveediin B; CHEMBL4634875
|
|
CAS | NA | |
PubChem CID | 156014455 | |
ChEMBL ID | CHEMBL4634875 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 238.28 | ALogp: | 2.4 |
HBD: | 3 | HBA: | 4 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 77.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 17 | QED Weighted: | 0.525 |
Caco-2 Permeability: | -4.779 | MDCK Permeability: | 0.00001820 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.307 | 20% Bioavailability (F20%): | 0.992 |
30% Bioavailability (F30%): | 0.996 |
Blood-Brain-Barrier Penetration (BBB): | 0.568 | Plasma Protein Binding (PPB): | 87.13% |
Volume Distribution (VD): | 0.736 | Fu: | 10.51% |
CYP1A2-inhibitor: | 0.813 | CYP1A2-substrate: | 0.478 |
CYP2C19-inhibitor: | 0.09 | CYP2C19-substrate: | 0.157 |
CYP2C9-inhibitor: | 0.069 | CYP2C9-substrate: | 0.68 |
CYP2D6-inhibitor: | 0.097 | CYP2D6-substrate: | 0.251 |
CYP3A4-inhibitor: | 0.097 | CYP3A4-substrate: | 0.103 |
Clearance (CL): | 10.087 | Half-life (T1/2): | 0.831 |
hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.029 |
Drug-inuced Liver Injury (DILI): | 0.047 | AMES Toxicity: | 0.288 |
Rat Oral Acute Toxicity: | 0.024 | Maximum Recommended Daily Dose: | 0.352 |
Skin Sensitization: | 0.92 | Carcinogencity: | 0.054 |
Eye Corrosion: | 0.848 | Eye Irritation: | 0.972 |
Respiratory Toxicity: | 0.841 |